NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Shares (Diluted, Weighted) for the year ending December 31, 2023: 82,161,956

NewAmsterdam Pharma Company N.V. Shares (Diluted, Weighted) is 82,161,956 for the year ending December 31, 2023, a 333.20% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

NewAmsterdam Pharma Company N.V. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 18,966,235, a 6.85% change year over year.
NewAmsterdam Pharma Company N.V. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 17,751,000, a 0.00% change year over year.
NewAmsterdam Pharma Company N.V. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 17,751,000.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years